口服普萘洛尔治疗婴幼儿腮腺区血管瘤的疗效观察  

Oral Medication of Propranolol for Infantile Parotid Hemangiomas

作　　者：孙桦梁[1,2] 刘晓红[3] 席善龙[1,2] 薛雷[1,2] 王绪凯[1,2] 

机构地区：[1]中国医科大学口腔医学院口腔颌面外科 [2]辽宁省口腔医学研究所口腔颌面外科研究室,辽宁沈阳110002 [3]吉林大学口腔医院牙体牙髓病科,吉林长春130021

出　　处：《口腔颌面外科杂志》2013年第6期463-466,共4页Journal of Oral and Maxillofacial Surgery

摘　　要：目的:对口服小剂量普萘洛尔治疗婴幼儿腮腺区血管瘤的临床疗效进行评价。方法:2009-10—2013-01,中国医科大学附属口腔医院收治30例腮腺区血管瘤患儿,普萘洛尔按1.0～1.5 mg/kg剂量,每天1次,口服,连续服用至瘤体缩小75%以上,随访1～10个月。收集每例患儿的相关资料,包括临床特征、疗效、不良反应。采用半球测量法和数码照片记录患儿血管瘤的大小,按家长反馈信息和4级评分法对疗效进行评价。结果:接受口服普萘洛尔治疗后,大部分腮腺区血管瘤的体积明显减小,家长满意度好,不良反应轻微。疗效评定结果Ⅳ级(优)18例,Ⅲ级(好)11例,Ⅱ级(中)1例,Ⅰ级(差)0例。结论:口服普萘洛尔可以作为治疗婴幼儿腮腺区血管瘤的首选治疗方法,疗效显著,用药安全。Objective： To assess the clinical efficacy of oral medication of propranolol in the treatment of infantile parotid proliferating hemangiomas. Methods： 30 infants with parotid proliferating hemangiomas treated with oral propranolol at a dose of 1.0-1.5 mg/kg/day were retrospectively reviewed. All the infants were followed up for a period of 1-month to 10- month. Informations including clinical characteristics, treatment modalities, and adverse reactions were collected. Hemisphere measurements and digital photos were used to record the size of hemangioma. 4 score method and feedback from parents have been used to evaluate the clinical curative effects. Results： Most tumors decreased in size with less adverse reactions. The overall response was scale IV （excellent） in 18 patients, scale ]l[ （good） in 11 patients, scale II （moderate） in 1 patients. No scale I （poor） patients. Conclusion： Oral medication of propranolol is a safe and effective way in the treatment of infantile parotid hemangiomas, especially for larger lesions.

关 键 词：血管瘤 普萘洛尔 腮腺 儿童 

分 类 号：R739.81[医药卫生—肿瘤]